Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94184ArticlesСтатьиResearch ArticleKlinicheskaya effektivnost' antagonistov mineralokortikoidnykh retseptorov v lechenii bol'nykh s khronicheskoy serdechnoy nedostatochnost'yuКлиническая эффективность антагонистов минералокортикоидных рецепторов в лечении больных с хронической сердечной недостаточностьюBernsS. AБернсС. АZverevK. VЗверевК. ВMyasnikovA. LМясниковА. ЛГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава РоссииГУЗ Городская клиническая больница №71 Департамента здравоохранения г. Москвы151020141610VOL 16, NO10 (2014)ТОМ 16, №10 (2014)768028122021Copyright ©; 2014, Consilium MedicumCopyright ©; 2014, ООО "Консилиум Медикум"2014Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94184

В статье приведены данные относительно основных патогенетических механизмов влияния альдостерона в развитии сердечной недостаточности и действия антагонистов минералокортикоидных рецепторов. С позиции доказательной медицины обсуждена эффективность использования антагонистов минералокортикоидных рецепторов в целом и эплеренона, в частности, при лечении пациентов с ХСН.

хроническая сердечная недостаточностьальдостеронантагонисты минералокортикоидных рецепторовБелоусов Ю.Б., Упницкий А.А., Ханина Н.Ю. Перспективные направления в лечении сердечной недостаточности. Качественная клин. практика. 2006; 1: 2-9.Zannad F, Mc Murray J.J.V, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Eng J Med 2011; 364: 11-21.Pitt B, Zannad F, Remme W.J et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.Parthasarathy H.K, Menard J, White W et al. A double blind, randomized study comparing the antihypertensive effect of Eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980-99.Hunt S.A, Abraham W.T, Chin M.H et al. ACC/AHA guideline update for the diagnosis and management of chronic heart failure in the adult. www.acc.org/clinical/guidelines/failure/indexChronic heart failure: management of chronic heart failure in adults in primary and secondary care. London: National Institute for Clinical Excellence (NICE), 2010. (Clinical guidelines, CG108).Weinberger M.H, Roniker B, Krause S.L et al. Eplerenone, a selective aldosterone blocker, in mild - to - moderate hypertension. Am J Hypertens 2002; 15: 709-16.Robert V, Ven Thiem N, Cheav S.L et al. Increased cardiac types I and III collagen mRNAs in aldosterone - salt hypertension. Hypertension 1994; 24: 30-6.Silvestre J, Heymes C, Abdesalam O et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99 (20): 2694-701.Chai W, Garrelds I.M, De Vries R et al. Non genomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension 2005; 46: 701-6.Brilla C, Weber K. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26: 671-7.Багрий А.Э., Лукашенко Л.В., Яковенко В.Г. Селективный антагонист альдостерона Инспра (эплеренон) в лечении больных, перенесших инфаркт миокарда. Медицина неотложных состояний. 2007; 2 (9).Yamaji M, Tsutamoto T, Kawahara C et al. Effect of Eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. Am Heart J 2010; 160 (5): 915-21.Gomez-Sanchez E.P, Ahmad N, Romero D.G et al. Origin of aldosterone in the rat heart. Endocrinology 2004; 145: 4796-802.Schepkens H, Vanholder R, Billiouw J.M et al. Life - threatening hyperkalemia during combined therapy with angiotensin - converting enzyme inhibitors and Spironolactone: an analysis of 25 cases. Am J Med 2001; 110: 438-41.Cruz C.S, Cruz A.A, Marcilio de Souza C.A. Hyperkalemia in congestive heart failure patients using ACE inhibitors and Spironolactone. Nephrol Dial Transplant 2003; 18: 1814-9.Pitt B, Bakris G, Ruilope L et al. on Behalf of the EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone post acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation 2008; 118: 1643-50.De Gasparo M, Joss U, Ramjoue H.P et al. Three new epoxyspirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240 (2): 650-6.Gardiner P, Schrode K, Quinlan D et al. Spironolactone metabolism: steady - state serum levels of the sulfur - containing metabolites. J Clin Pharmacol 1989; 29 (4): 342-7.Brown N.J. Eplerenone: cardiovascular protection. Circulation 2003; 107 (19): 2512-8.Sica D.A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005; 10 (1): 23.Swedberg K, Eneroth P, Kjekshus J et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82: 1730-6.Tsai C.T, Chiang F.T, Tseng C.D et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 2010; 55: 758-70.Lendeckel U, Dobrev D, Goette A. Aldosterone - receptor antagonism as a potential therapeutic option for atrial fibrillation. Br J Pharmacol 2010; 159: 1581-3.Agostoni P, Emdin M, Corra U, et al. Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients. Eur Heart J 2008; 29: 2367-72.Clark D.M, Plumb V.J, Epstein A.E et al. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997; 30: 1039-45.Swedberg K, Zannad F, Mc Murray J.J.V et al. Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. Results From the EMPHA- SIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure). J Am Coll Cardiol 2012; 59 (18): 1598-603.Poole-Wilson P.A, Swedberg K, Cleland J.G et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo - controlled study. Lancet 2010 376: 875-85.Iqbal J, Fay R, Adlam D et al. Effect of eplerenone in percutaneous coronary intervention - treated post - myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPH- ESUS trial. Eur J Heart Fail 2014; 16: 685-91.Danjuma M.I, Mukherjee I, Makaronidis J et al. Converging Indications of Aldosterone Antagonists (Spironolactone and Eplerenone): A Narrative Review of Safety Profiles. Curr Hypertens Rep 2014; 16: 414.